The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
Open accessAbstract
CA 19-9 and CEA are the most commonly used biomarkers for diagnosis and management of patients with pancreatic cancer. Since the original compendium by Steinberg in 1990, numerous studies have reported the use of CA 19-9 and, to a lesser extent, CEA in the diagnosis of pancreatic cancer. Here we update an evaluation of the accuracy of CA 19-9 and CEA, and, unlike previous reviews, focus on discrimination between malignant and benign disease instead of normal controls. In 57 studies involving 3,285 pancreatic carcinoma cases, the combined sensitivity of CA 19-9 was 78.2% and in 37 studies involving 1,882 cases with benign pancreatic disease the specificity of CA 19-9 was 82.8%. From the combined analysis of studies reporting CEA, the sensitivity was 44.2% (1,324 cases) and the specificity was 84.8% (656 cases). These measurements more appropriately reflect the expected biomarker accuracy in the differential diagnosis of patients with periampullary diseases. We also present a summary of the use of CA 19-9 as a prognostic tool and evaluate CA 19-9 diagnostic and prognostic utility in a 10-year, single institution experience.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Colorectal carcinoma antigens detected by hybridoma antibodies
Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., & Fuhrer, P. (1979) · Somatic Cell Genetics · doi:10.1007/bf01542654 · Cited by 1,364
Goonetilleke, K. S., & Siriwardena, A. K. (2007) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2006.10.004 · Cited by 877
Specific Antigen in Serum of Patients with Colon Carcinoma
Koprowski, H., Herlyn, M., Steplewski, Z., & Sears, H. F. (1981) · Science · doi:10.1126/science.6163212 · Cited by 591
(1990) · PubMed · Cited by 579
Ferrone, C. R., Finkelstein, D. M., Thayer, S. P., Muzikansky, A., Castillo, C. F.-D., & Warshaw, A. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3934 · Cited by 554
Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.
Del Villano, B. C., Brennan, S., Brock, P., Bucher, C., Liu, V, McClure, M., Rake, B., Space, S., Westrick, B., Schoemaker, H., et al. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.549 · Cited by 506
Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
Tempero, M. A., Uchida, E., Takasaki, H., Burnett, D. A., Steplewski, Z., & Pour, P. M. (1987) · PubMed · Cited by 400
KIM, J., LEE, K. T., LEE, J. K., PAIK, S. W., RHEE, J. C., & CHOI, K. W. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03219.x · Cited by 394
Cited by
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Allenson, K., Castillo, J., San Lucas, F. A., Scelo, G., Kim, D. U., Bernard, V., Davis, G., Kumar, T., Katz, M., Overman, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx004 · Cited by 493
Maher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., Molyneaux, P. L., Braybrooke, R., Divyateja, H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30430-7 · Cited by 271
Yu, S., Li, Y., Liao, Z., Wang, Z., Wang, Z., Li, Y., Qian, L., Zhao, J., Zong, H., Kang, B., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318860 · Cited by 241
Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection
Fahrmann, J. F., Schmidt, C. M., Mao, X., Irajizad, E., Loftus, M., Zhang, J., Patel, N., Vykoukal, J., Dennison, J. B., Long, J. P., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.052 · Cited by 208
Metadata
- Authors
- E. Poruk, K., Z. Gay, D., Brown, K., D. Mulvihill, J., M. Boucher, K., L. Scaife, C., A. Firpo, M., & J. Mulvihill, S.
- Venue
- Current Molecular Medicine
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-02-01
- Volume
- 13
- Issue
- 3
- Pages
- 340-351
- ISSN
- 1566-5240 (ISSN-L)
- OpenAlex
- W2159407099
- Cited by
- 398
- References
- 57
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates. https://app.cochat.ai/papers/10.2174/1566524011313030003
- The paper
- E. Poruk, K., Z. Gay, D., Brown, K., D. Mulvihill, J., M. Boucher, K., L. Scaife, C., A. Firpo, M., & J. Mulvihill, S. (2013). The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates. Current Molecular Medicine. https://doi.org/10.2174/1566524011313030003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
